Phase III MEDALIST: Erythroid Maturation Agent Luspatercept in Very Low– to Intermediate-Risk Myelodysplastic Syndrome With Ring Sideroblasts

December 1-4, 2018; San Diego, California
Luspatercept significantly reduced transfusion burden and improved hemoglobin levels compared with placebo for transfusion-dependent anemia in patients with lower-risk myelodysplastic syndrome with ring sideroblasts.
Format: Microsoft PowerPoint (.ppt)
File Size: 184 KB
Released: December 17, 2018


Provided by the Annenberg Center for Health Sciences at Eisenhower.

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Supported by educational grants from
Celgene Corporation
Dova Pharmaceuticals, Inc.
Gilead Sciences
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs
Seattle Genetics
Takeda Oncology

Related Content

Download this short summary slideset of key topics in the evolving use of BCMA-targeted agents for RR multiple myeloma from Clinical Care Options.

Natalie S. Callander, MD Released: October 23, 2020

Clinical commentary by Dr. William Wierda on personalizing frontline treatment for chronic lymphocytic leukemia (CLL) from Clinical Care Options (CCO)

William G. Wierda, MD, PhD Released: October 22, 2020

Downloadable resource from CCO on the diagnosis and management of mycosis fungoides

Prof Julia Scarisbrick Released: October 21, 2020

Download this slideset to review the latest clinical data informing optimal management strategies for follicular lymphoma

Emily Bucholtz Headshot Emily Bucholtz, RPh Nichole Fisher Headshot Nichole Fisher, RN, BSN Jeff P. Sharman, MD Released: October 14, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.